Orsini - Rare Disease Pharmacy Solutions

Background

Founded in 1987, Orsini is a leading independent specialty pharmacy dedicated to providing comprehensive and compassionate care for patients with rare diseases and those undergoing gene therapies. The company's mission is to ensure that "No Patient is Left Behind™," emphasizing personalized support and access to advanced treatments. Orsini collaborates closely with biopharmaceutical innovators, healthcare providers, and payors to streamline the connection between patients and revolutionary therapies. Their high-touch care model focuses on therapy-specific care teams that deliver individualized patient care, enhancing treatment adherence and outcomes.

Key Strategic Focus

Orsini's strategic focus centers on delivering integrated rare disease pharmacy solutions, including:

Pharmacy Distribution: Efficient and secure distribution of specialty medications tailored for rare conditions.

Patient Services: Comprehensive support programs designed to assist patients throughout their treatment journey.

Clinical Management: Expert clinical oversight to ensure optimal therapeutic outcomes.

Home Infusion Services: Nationwide nursing coverage providing convenient in-home infusion therapies.

By focusing on these areas, Orsini aims to simplify the process through which patients access and adhere to complex therapies, thereby improving overall health outcomes.

Financials and Funding

In February 2022, The Carlyle Group acquired a stake in Orsini Specialty Pharmacy, joining Consonance Capital as approximately equal investors. This investment underscores the growing interest in specialty pharmacies that manage the distribution and service requirements of high-cost, complex pharmaceuticals, particularly those targeting ultra-rare diseases.

Technological Platform and Innovation

Orsini has developed ORBIT™ (Orsini Rare Business Intelligence Technology), an advanced AI-enabled reporting and analytics platform designed to enhance patient care for those living with rare diseases. ORBIT™ leverages artificial intelligence to provide deeper insights and more personalized support, enabling pharmaceutical manufacturers to better understand and address the unique needs of rare disease patients. The platform integrates real-world data collection with robust analytics and reporting capabilities, facilitating informed decision-making and improved patient engagement and adherence.

Leadership Team

Brandon Tom, Chief Executive Officer: Brandon leads Orsini with a focus on expanding partnerships and enhancing patient care services.

Ashok Singh, Chief Information Officer: Appointed in April 2024, Ashok is responsible for implementing technology enhancements aimed at driving innovation in rare disease patient care through AI-enabled technology.

Darin DeCarlo, Chief Commercial Officer: Darin oversees commercial strategies, including partnerships and market expansion initiatives.

Leadership Changes

In April 2024, Ashok Singh joined Orsini as Chief Information Officer, bringing expertise in technology-driven healthcare solutions. His appointment aligns with Orsini's commitment to leveraging advanced technologies to enhance patient care.

Competitor Profile

Market Insights and Dynamics

The specialty pharmacy market has experienced significant growth, driven by advancements in genomics and biotechnology leading to the development of therapies for rare diseases. Specialty drugs, often high-cost and complex, require specialized handling and patient support services, positioning specialty pharmacies like Orsini as critical players in the healthcare ecosystem.

Competitor Analysis

Key competitors in the specialty pharmacy sector include:

CVS Specialty: A division of CVS Health, offering a broad range of specialty pharmacy services.

Accredo Health Group: A specialty pharmacy subsidiary of Express Scripts, focusing on complex and chronic conditions.

Walgreens Specialty Pharmacy: Provides specialized pharmacy services for patients with complex health conditions.

These competitors offer comprehensive specialty pharmacy services, including medication management, patient education, and adherence programs.

Strategic Collaborations and Partnerships

Orsini has established several strategic partnerships to enhance its service offerings:

PicnicHealth: In January 2025, Orsini partnered with PicnicHealth to develop drug-specific registries combining real-world drug data, curated electronic medical records, and patient-reported outcomes. This collaboration aims to provide deeper insights into patient treatment journeys and medication adherence.

AstraZeneca: Orsini serves as the exclusive specialty pharmacy partner for WAINUA™ (eplontersen), an FDA-approved treatment for adults with hereditary transthyretin-mediated amyloid polyneuropathy.

KalVista Pharmaceuticals: In July 2025, Orsini was selected as a specialty pharmacy partner for EKTERLY® (sebetralstat), an FDA-approved oral therapy for the treatment of acute attacks of hereditary angioedema.

Operational Insights

Orsini's commitment to quality and patient safety is demonstrated through its accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and the National Association of Boards of Pharmacy (NABP). Notably, Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs, reflecting its dedication to excellence in rare disease pharmacy services.

Strategic Opportunities and Future Directions

Orsini is poised to capitalize on the growing demand for specialty pharmacy services, particularly in the realm of rare diseases and gene therapies. By leveraging technological innovations like ORBIT™ and expanding strategic partnerships, Orsini aims to enhance patient care, improve treatment adherence, and streamline access to complex therapies. The company's focus on personalized, high-touch care positions it to meet the evolving needs of patients and healthcare providers in the specialty pharmacy landscape.